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Translation of results from genetic findings to inform medical practice is a highly
anticipated goal of human genetics. The aim of this paper is to review and discuss the role
of genetics in medically-relevant prediction. Germline genetics presages disease onset
and therefore can contribute prognostic signals that augment laboratory tests and clinical
features. As such, the impact of genetic-based predictive models on clinical decisions
and therapy choice could be profound. However, given that (i) medical traits result from a
complex interplay between genetic and environmental factors, (ii) the underlying genetic
architectures for susceptibility to common diseases are not well-understood, and (iii)
replicable susceptibility alleles, in combination, account for only a moderate amount of
disease heritability, there are substantial challenges to constructing and implementing
genetic risk prediction models with high utility. In spite of these challenges, concerted
progress has continued in this area with an ongoing accumulation of studies that
identify disease predisposing genotypes. Several statistical approaches with the aim of
predicting disease have been published. Here we summarize the current state of disease
susceptibility mapping and pharmacogenetics efforts for risk prediction, describe methods
used to construct and evaluate genetic-based predictive models, and discuss applications.
Keywords: predictive model, genetic risk, human genetics, prognosis, clinical utility
INTRODUCTION AND BACKGROUND
Multiple lines of evidence strongly support the notion that the
large majority of common, chronic diseases have complex causes.
Environmental components such as infection, caloric flux, and
chemical exposure, along with heritable elements such as DNA
variants, methylation patterns, and epigenetic RNA effects, are
interacting co-conspirators resulting in common diseases. In
this background of convoluted and entangled etiology, discov-
ery and use of disease predisposing alleles present a consid-
erable challenge to the human genetics community (Clerget-
Darpoux and Elston, 2013). Recent technological advances in
high-throughput genotyping, RNA expression, and massively
parallel sequencing have accelerated interrogation of genetic vari-
ation for the purpose of understanding human disease and drug
response. Among the more important uses of these discover-
ies is providing detailed, mechanistic insight into the molec-
ular pathogenesis of disease states. The two primary avenues
of utilizing this explosion in genetic information for the pur-
pose of improving clinical practice are in (1) drug development
†This is inspired by a humorous quote that is variably attributed to Mark
Twain, Niels Bohr, the Danish Parliament, Samuel Goldwyn, and Yogi Berra.
stemming from the identification of molecular targets and (2) the
prediction of disease susceptibility, pharmacogenetic response,
and disease severity/trajectory (Khoury et al., 1985; Holtzman
and Marteau, 2000; Evans and Relling, 2004). Although only
a small minority of current pharmaceuticals originated directly
from genetic findings serving as drug targets, the list is expanding
and includes inflammatory cytokine-based monoclonal antibod-
ies and targeted cancer therapeutics, among others. These ther-
apeutics often target specific biochemical pathways to improve
clinical treatment, often with a reduction in adverse reactions.
Disease prediction and diagnosis with genetic testing is a broad
field with diverse applications, ranging from karyotyping for
chromosomal abnormalities to enhancement of disease risk pro-
files using single nucleotide polymorphisms (SNPs) previously
found to be disease-susceptibility markers, such as HFE missense
polymorphisms which can lead to hemochromatosis, or the vari-
ants in the tumor suppressors BRCA1 and BRCA2 that increase
risk to breast and ovarian cancers. Clinical genetics testing can
provide physicians with an additional tool for better diagnosis
and improved medical care.
Much of the variation in disease course, severity, and response
to medication is reflective of the underlying allelic repertoire
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existing in each individual, offering the opportunity for genet-
ics to facilitate early treatment, preventative medicine, preemptive
selection of efficacious drugs, and more accurate estimation of
risk for those thought to be at intermediate risk using traditional
factors. As the cost and complexity of medical care escalates,
the promise of human genetics to provide directly actionable,
individualized information to address impediments to optimal
and cost-effective medical practice carries increasing weight and
urgency (Chen and Snyder, 2013). This review has multiple aims:
(1) provide a brief overview of the current state of human dis-
ease mapping as this provides the foundational knowledge for
genetic-based disease prediction, (2) describe the process of dis-
ease prediction in a simple probabilistic framework detailing the
general qualities of clinically useful predictive models and also
detailed examples, (3) provide an overview of the basic classes of
genetic-based prediction models and measures of prognostic util-
ity, and (4) illustrate the application of genetic-based predictive
models to data from biobanks and prospective cohorts.
Identification of replicated susceptibility variants provides
considerable material for understanding biochemical pathways
that govern diseases, particularly when the variants reside within
the coding or regulatory regions of well-understood genes and are
validated by functional studies (Manolio, 2010). Unfortunately,
many disease-associated variants are located in regions of the
genome that have not yet been functionally characterized.
Indeed, 39% of the National Human Genome Research Institute
(NHGRI) Genome-Wide Association Study (GWAS) catalog
SNPs are annotated as intergenic andmore than 36% are reported
as intronic (Welter et al., 2014). The genes and pathways dis-
covered can become targets for pharmaceutical intervention,
especially when integrated with corroborating studies from dis-
ease models, signal transduction experiments, bioinformatics,
and protein biochemistry. Examples of using specific genes or
their products as pharmaceutical targets have rapidly accumu-
lated over the past decade and include mipomersen, an antisense
therapeutic targeting APOB RNA for the treatment of hyper-
cholesterolemia (Raal et al., 2010), ivacaftor which targets the
G551D mutation in CFTR found in approximately 4% of indi-
viduals with cystic fibrosis (Ramsey et al., 2011), inflammatory
cytokines and their receptors (e.g., IL-1β, IL-12/23p40, IL-17A,
IL-6R) (e.g., Krueger et al., 2007), other immune cell signaling
proteins (e.g., CTLA-4, CD30), a variety of tumorigenesis genes
that harbor somatic variants useful for individualized cancer
treatment (e.g., BRAF, KRAS, and EGFR), and lipid transfer pro-
teins (e.g., CETP, PCSK9), among many others. As more human
genetics studies are conducted, the number of these druggable
targets will expand.While the use of genetic results in pharmaceu-
tical development is impressive, some of the most highly touted
uses of genetic susceptibility data have been the accurate progno-
sis of diseases (e.g., Mendelian and oligogenetic disorders, such
as Tay-Sachs disease, phenylketonuria, Charcot-Marie-Tooth, or
rare ciliopathies including polycystic kidney disease and Bardet-
Biedl syndrome), or other areas that impact medical decisions,
such as choice of drug, selection of dose, avoidance of side-effects,
or determining the optimal intensity of clinical monitoring.
Unlike identifying potential drug targets, genetic-based predic-
tion models may serve a clinical purpose in advance of precise
identification of the functional motifs andmolecular mechanisms
that drive genetic association/linkage signals. Instead, the util-
ity of predictive models is derived primarily from the correlation
patterns—provided that these are robust across intended popula-
tions. However, the strength and robustness of the correlation are
critical for a genetic prediction model to be clinically useful.
As clinical decisions are specific to individuals, physicians aim
to assess the probability of medical traits for each patient. This is
a dynamic process where physicians update assessments as addi-
tional relevant information, such as laboratory tests (both genetic
and non-genetic), or changes in physiology become known. In
this way, clinical decisions are informed as variation in an individ-
ual’s risk to disease, severity of disease and response tomedication
are progressively revealed. Thus, results from clinical tests, includ-
ing genetic-based predictive models, are useful when they more
accurately discern the likelihood of the medical trait (e.g., disease
occurrence or response to medication), compared to the pre-
test assessment. For example, if a physician had estimated that a
patient had a 40% chance of having a particular disease prior to
the results of a clinical test, and the 40% prediction remains unal-
tered following the results of the test, then the clinical test and new
prediction may be of little value. Further, whether the magnitude
of this posterior-prior probability departure carries clinical utility
depends on the specific application. As an illustration of this pro-
cess, suppose a patient is referred to a rheumatologist. Prior to the
visit, the rheumatologist may not have sufficient information to
modify the assessment of the probability that the individual has,
for example, rheumatoid arthritis (RA). Upon learning that the
patient self-reported symptoms of symmetric sore joints that are
partially remediated by non-steroidal anti-inflammatory medica-
tion, the rheumatologist proceeds to update the probability of RA
and of other conditions. Some diseases would increase in their
likelihood, while others would decrease from their initial values.
Following a standard evaluation of the classification criteria for
rheumatoid arthritis assessing joint involvement, serology, acute-
phase reactants, and symptom duration (Aletaha et al., 2010),
the rheumatologist proceeds to further update the probability
that the patient suffers from RA. Subsequent testing of a genetic
panel of known RA-susceptibility markers, including polymor-
phisms within HLA-DRB1, PTPN22, STAT4, CTLA4, TRAF1,
CD40, etc., may further modify the posterior probability. This
additional updated posterior probability may be particularly use-
ful in situations where a definitive diagnosis was not available with
non-genetic approaches alone. This is, of course, neither a new
nor complete account of the diagnostic process, but it underscores
the general nature of many medical decisions, where accumu-
lation of information typically results in increasing accuracy in
the appraisal of a medical trait probability for an individual. The
process of serial refinement based on accumulating data is a hall-
mark of the diagnostic process and, statistically, can be codified
as Bayesian updating of the posterior probability of the trait. The
aim of genetic-based predictive models is to augment existing lab-
oratory, imaging, and other clinical data to improve the posterior
probabilities (i.e., drive the posterior probabilities toward 0 or 1)
of medical traits in a cost-effective manner.
In the context discussed here, predictive models are methods
designed to use clinical, analyte, genetic, or other types of data for
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the purpose of forecasting a medical trait. Predictive models—
including those based on genetic markers—are most beneficial
when they yield actionable and individualized results. However,
they are of reduced value if they only substantially modify medical
decisions for an exquisitely small fraction of the patient popula-
tion. Hence, the ideal genetic-based predictive model for clinical
applications (1) substantially modifies the posterior probability
of medical traits compared to that obtained from existing clini-
cal assessment and tests—enough to enable changes in medical
decisions and patient management, and (2) impacts a substan-
tial fraction of individuals to whom it is applied and provides
improved outcomes. While other considerations are essential,
such as more cost-effective care and the ease of adoption and
implementation of diagnostic tests, it is this concurrent maxi-
mization of (1) modifying the posterior probability of the trait
in the context of the benefits and risks of the specific medical
decisions and (2) broad applicability that defines an archety-
pal genetic-based predictive model. For example, genetic testing
of CFTR mutations for cystic fibrosis is successful in that the
recessive disease alleles have very high penetrance and the large
majority of pathogenic mutations are covered with contempo-
rary panels. Similarly, multi-gene tests for related rare diseases,
each with high penetrance, can also serve as useful clinical tests
(Rehm, 2013).
In an attempt to develop such predictive models, many have
used genome-wide association study (GWAS) results as they are
a ubiquitous source of genetic information (Manolio, 2010).
Attempts to use genetic information alone have not been as
successful as previously hoped, with posterior probabilities that
do not approach 1 or 0 and the vast majority of individuals
having decidedly intermediate posterior probabilities. A seminal
question is the extent to which genetic information can further
modify posterior probabilities for those individuals thought to
be of intermediate risk using traditional factors. Wray et al. offer
an excellent review of the challenges involved in complex trait
prediction with GWAS results (Wray et al., 2013).
The discovery of genetic markers for the prediction of medi-
cal traits is entirely dependent on the underlying genetic model
that gives rise to the trait. That is, the number of loci and the
number, frequency and penetrance of predisposing alleles deter-
mine both the likelihood of identifying causal markers and the
clinical utility of using those markers in a patient population.
For example, monogenic disorders such as phenylketonuria, Tay-
Sachs, or sickle cell anemia are likely fully penetrant with allele
frequencies that are not exceedingly rare; and therefore genetic
tests for such diseases have clinical applications, provided that dis-
ease avoidance or disease-modifying treatments exist. However,
traits like Alzheimer’s disease, diabetes, or response to statins
have etiologies that remain enigmatic. Whether or not these
complex traits follow extremely polygenic modes of inheritance
(i.e., weakly penetrant alleles, and several hundreds to thousands
of loci), high locus/allelic heterogeneity (having highly pene-
trant but unique loci and alleles involved across individuals),
high levels of epistasis (e.g., genotypic effects that vary based
on genetic background or other specific genotypes), ubiquitous
epigenetic effects (e.g., methylation patterns, histone acetylation
patterns, or transgenerational RNA artifacts affecting the trait),
gene-environment interactions, or some combination thereof,
directly impacts the identification of predictive markers as well
as their utility. GWAS interrogate the common allelic architec-
ture for disease predisposing markers exhibiting low degrees of
allelic and locus heterogeneity, whereas sequencing-based studies
in families can facilitate the discovery of rare disease-associated
variants, but are not optimal for identifying ancestral disease-
predisposing alleles. Therefore, it is reasonable to expect that
genetic markers from GWAS may modify posterior probabilities
across a large segment of the population, but with amuted impact
on those probabilities. On the other hand, rare sequence variants,
on the other hand, may have substantial impact on the posterior
probabilities for specific individuals, but with little widespread
effect.
A review of the potential of genetic-based predictive mod-
els to change medical practice in the short-term indicates that
three areas have shown promise for improving clinical care: can-
cer genomics, population screening for Mendelian diseases, and
pharmacogenetics. These three areas profit from high penetrances
of the genetic variants identified to date, though only a fraction of
patients benefit from these tests. As these areas emerge from their
infancy and additional genetic results accumulate, the proportion
of individuals benefiting will likewise increase.
PREDICTION USING TUMOR GENOMICS
The advent of genetic testing in tumor cells, through harnessing
the throughput and read depth of next-generation sequencing
platforms, has enabled detailed and clinically actionable molec-
ular pathology genetic tests for numerous cancers. Multiplex
sequencing-based assays for biopsies compared to normal tis-
sue are now available and have demonstrated usefulness in
augmenting many clinical decisions. The utility of these tests
relies on the clear relationship that has been delineated over
the past two decades between specific driver mutations, treat-
ment variants and cancer progression, and drug selection (Liaw
et al., 1997; Paez et al., 2004; Agrawal et al., 2011; Walter et al.,
2012; Kandoth et al., 2013; Vogelstein et al., 2013). Intratumor
(Gerlinger et al., 2012) and single-cell sequencing methods
(Navin et al., 2011) offer the possibility of inferring the evo-
lutionary history and driver mutations in clonal expansions of
cancer cells. These techniques have been successfully applied to
several cancers with excellent prognostic utility, for example,
kidney cancer (Xu et al., 2012). For well-defined activating muta-
tions such as those within BRAF (Loupakis et al., 2009; Borras
et al., 2011), KRAS (Linardou et al., 2008) and EGFR (Lynch
et al., 2004), the posterior probability of efficacious treatment
selection is also high. Indeed, there seems to be a clear path
to incorporating panels of well-defined oncogenesis, metastasis,
and drug response variants through next-generation sequencing
of tumors. Baylor College of Medicine, one institution among
several offering a number of clinical genetics tests, has devel-
oped a Cancer Gene Mutation Panel through next-generation
sequencing that investigates 2855 known mutations within 50
cancer-associated genes for clinical testing (http://www.bcm.edu/
cancergeneticslab/test_detail.cfm?testcode=9705). Other efforts
include the UCLA Clinical Genomics Center (http://pathology.
ucla.edu/body.cfm?id=105), the Emory Genetics Laboratory
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(http://genetics.emory.edu/egl/), and the Washington University
School of Medicine (http://gps.wustl.edu/). Identification of a
small number of specific mutations enables selective treatment
courses to be taken with higher expected efficacy, albeit often with
limited duration of effect due to the development of drug resis-
tance, an expected consequence of monotherapy. For example,
in this Baylor panel BRAF mutations are targeted, where treat-
ment with vemurafenib and dabrafenib has demonstrated BRAF
Val600-specific metastatic melanoma antitumor activity (Jang
and Atkins, 2013). Over the past five years, somatic cell and tumor
genomics has provided remarkable insights into the molecular
pathobiology of cancers. This rapidly progressing field contin-
ues to accumulate examples of improved treatment resulting from
these genetic discoveries.
PREDICTION IN SCREENING FOR MENDELIAN DISORDERS
Equally impressive has been the progress in interrogating very
highly penetrant alleles in population-based screens, particu-
larly in newborns. Next-generation sequencing has enabled rapid,
cost-effective multiplex assays that require little DNA. Given the
high positive predictive value of these variants and the ability
to modify clinical treatment in many of these Mendelian dis-
orders, genetic-based prediction in this area is an efficacious
addition to medical practice. For example, Saunders et al. recently
showed the feasibility of screening for monogenic diseases across
the genome within 50 h in a neonatal clinical setting (Saunders
et al., 2012). Importantly, infants identified as having pathogenic
genotypes (e.g., Kwan et al., 2013; Stefanutti et al., 2013) can
receive appropriate treatment while still hospitalized, often avoid-
ing life-threatening complications. Comprehensive genetic test-
ing may preclude emotionally and financially costly pediatric
odysseys (Kingsmore et al., 2011). In addition, the application
of high-throughput sequencing approaches to clinically impor-
tant, expansive gene panels can reliably identify known inherited
pathogenic variants and new germline mutations that are poten-
tially pathogenic, thereby driving effective early screening (Kurian
et al., 2014).
PREDICTION IN PHARMACOGENETICS
Pharmacogenetics is the third area in which genetic variants can
enable physicians to differentially prescribe certain medications
to individuals to avoid adverse events or to modify dosing. The
importance of these genetic variants in avoiding adverse drug
reactions is underscored by FDA black-box warnings (http:
//www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmaco
genetics/ucm083378.htm), as well as by recommendations
of other groups (https://www.pharmgkb.org/). For example,
individuals carrying the HLA-B∗5701 allele are warned against
taking abacavir (Mallal et al., 2008), dapsone-treated patients
with certain G6PD variants are at higher risk for hemolysis as
are patients receiving primaquine, many sulfonamides, nitro-
furantoin, acetanilide, niridazole, and naphthalene (Cappellini
and Fiorelli, 2008), and the beta blocker propranolol can cause
adverse reactions in those with variants conferring compromised
CYP2D6 function (Cascorbi, 2003; Samer et al., 2013). In all,
the FDA currently lists 155 pharmacogenetic warnings across
numerous therapeutic areas. Again, the validated, high positive
predictive value of these pharmacogenetic variants makes
immediate clinical utility possible, if not immediately actionable.
Clinically useful genetic variants underlying other pharmacoge-
netic traits, such as differential response to many lipid-modifying
medications, metformin, and anti-TNF therapies, still remain
largely abstruse.
Importantly, the setting of clinical application of genetic tests
is critical to the usefulness of genetic-based predictive models.
Traits, including drug response and adverse reactions, that are
(1) otherwise easily diagnosed, or (2) for which disease man-
agement would not change with the results of the predictive
model, are poor candidates for these predictive models. So, results
from the use of genetic-based predictive models must serve as
a cog in the health management machinery and clearly satisfy
an unmet medical need. For example, genetic-based predictive
models are unlikely to play a useful role in diagnosing a bone frac-
ture. Similarly, Kimmel et al. recently showed that even though
genetics can fairly accurately predict warfarin sensitivity, this
information offers no benefit over clinical management of war-
farin dosing to achieve therapeutic range (Kimmel et al., 2013).
The setting of medical care also plays an important role: nearly
half of all patients are not treated in coagulation centers, leaving
the question of how diagnostic genetic testing would fare in those
environments.
Why is it that these three above areas have enjoyed more suc-
cess in applying genetic information to clinical practice than other
applications, such as prognosis of complex diseases? In large part,
the answer lies in the relatively low complexity of the genetic
architecture behind these medical traits. The propagation of can-
cer cells, tumor survival and metastasis are promoted by specific
mutations that wield strong effects on promoting clonal expan-
sions: driver mutations. Different driver mutations accomplish
this task in different ways, but each driver mutation has pro-
found effects on cellular metabolism, mitosis, and proliferation.
Because the effects of these driver mutations are profound and
characteristic of specific molecular pathophysiologies, it is not
surprising that they are reasonably predictive of disease trajectory
and chemotherapy response. Similarly, provided that the false
positive rate of prognostic tests is low, population-based screens
for Mendelian disorders have been a useful addition to modern
medical practice because the penetrance of such traits is typically
complete or nearly complete. That is, aside from the measure-
ment error rates, the prediction of disease given a positive genetic
test is accurate and reliable. Finally, although not as definitive as
Mendelian disorders, pharmacogenetic effects identified to date
testify to reduced complexity of these traits. This is particularly
true of extreme adverse events (e.g., FDA black box warnings)
and response with those drugs having highly targeted substrates.
In contrast, therapeutics with multifold actions, such as statins
or metformin, have exhibited much more recalcitrance to genetic
dissection.
In contrast to the above-mentioned areas, currently the predic-
tion of common diseases presents a considerable challenge. Most
common diseases have been relatively reluctant to reveal a large
fraction of the genetic component of their etiologies (Manolio
et al., 2009). Several studies of complex diseases have shown lit-
tle improvement to disease prediction when adding genetic data
Frontiers in Genetics | Applied Genetic Epidemiology June 2014 | Volume 5 | Article 162 | 4
Schrodi et al. Genetic-based prediction of disease
to already established disease risk factors (e.g., Thanassoulis and
Vasan, 2010; Bao et al., 2013; Muhlenbruch et al., 2013); and,
even if statistically significant, the models incorporating genetic
information may not be clinically useful (Husing et al., 2012).
While there are several instances of important, influential mark-
ers that have been discovered in some common diseases, such
as APOE in Alzheimer’s, ARMS2 and CFH in age-related mac-
ular degeneration (AMD), and numerous alleles in the MHC
region for autoimmune and inflammatory diseases, many genetic
linkage results are the result of multiple infrequent alleles and
most replicated markers from GWAS have modest effect sizes.
In combination, the replicated disease susceptibility alleles dis-
covered thus far have yet to demonstrate substantial prognostic
utility. That said, there are encouraging exceptions: the combined
effect of the multiple identified loci for AMD or Crohn’s disease
may offer some clinical utility in selected circumstances. AMD
is a leading cause of compromised vision and blindness, and
individuals at heightened risk for AMD can benefit from more
frequent eye exams and early treatment to curb the likelihood
of permanent ophthalmic damage. Administration of anti-VEGF
monoclonal antibodies have shown efficacy in exudative AMD
treatment (Fung et al., 2007; Heier et al., 2012). Recent GWAS
studies in AMD have demonstrated that the 19 top AMD risk loci
are estimated to explain between 15 and 65% of the genetic por-
tion of the variance in the phenotype (the proportion depends
on the assumption of AMD prevalence being between 0.01 and
0.10). This set of SNPs also generates an area under the ROC
curve (AUC) of 0.74 (Fritsche et al., 2013), meaning that if you
choose pairs of people at random, one with and one without
AMD, and used their SNP data, the one with a higher probabil-
ity of AMD would in fact be the one with AMD 74% of the time
(Berrar and Flach, 2012). Incorporation of other known risk fac-
tors, such as age and smoking, further improves this prediction.
It is possible that other measures, including positive and negative
predictive values or those based on posterior probability distri-
butions, could provide better insight into clinical utility. Another
promising area is the use of all genetic variants genotyped in a
genome-wide array to construct predictive models, rather than
restricting the markers to those that are strongly associated with
the trait. Purcell et al. investigated the use of thousands of com-
mon alleles in predictive models for schizophrenia and bipolar
disorder, demonstrating an increase in the proportion of themax-
imum variance in these traits explained as the trait-association
significance level was relaxed (Purcell et al., 2009). In addition,
analysis of the Wellcome Trust Case Control Consortium data
for Crohn’s disease appeared to indicate that expansion of the
number of SNPs in a predictive model over just those reach-
ing genome-wide significance improves the model performance
(Kooperberg et al., 2010). These are interesting observations and
consistent with results from Yang et al. (2010) and Lee et al.
(2011) describing the rather dramatic increase in the proportion
of heritability explained with all GWAS SNPs compared to top
SNP findings. Wei et al. offer a recent example of harnessing this
effect for Crohn’s disease where expanding the number of variants
and using advanced machine learning techniques increased pre-
dictive accuracy (Wei et al., 2013). With greater resolution, Yang
et al. (2011) showed that the length of chromosomes is linearly
correlated with the percentage of the variance attributable to a
variety of phenotypes, including von Willebrand factor, height,
BMI andQT interval. However, both theoretical and applied work
appears to show limited utility of including more than a few
hundred SNPs in commonly-used predictive models (Wu et al.,
2013; Warren et al., 2014). Nonetheless, methods that exploit the
whole genome for disease prediction, such as extensions to Best
Linear Unbiased Prediction (BLUP), continue to develop andmay
improve accuracymetrics for both binary disease and quantitative
traits (Zhang et al., 2014).
UTILITY AND METHODS
Given that for many diseases with effective treatments accurate
prediction of potential disease can play a critical role in deter-
mining robust clinical care that may avert severe disease or even
disease onset, it is essential to characterize the important aspects
that produce useful predictive models. For traits with polygenic
etiologies, methods must be used to combine signals from multi-
ple genetic markers together into a cohesive metric for prediction
(Wimmer et al., 2013). Seven main considerations when doing
so are: (1) which genetic markers are to be included in the pre-
dictive model—i.e., feature selection, (2) the frequencies of the
susceptible/protective genotypes at each selected marker, (3) the
strength of the correlation between the genotypes at each marker
and the predicted trait, (4) the interactions between the effects
sizes of different genetic markers, (5) the prevalence of the trait
being predicted, (6) how the genetic data are envisioned to inte-
grate into clinical practice in combination with non-genetic tests,
and (7) a determination of the robustness of the prognostic
signal across multiple populations, including those with varied
ancestries. Over the past decade, several methods have been pro-
posed to accomplish these tasks, including genetic risk scores,
various types of regression-based approaches, Bayesian networks,
and other machine learning methods. Importantly, polygenic
disease-prediction models may serve as instrumental variables
for Mendelian randomization analyses in the investigation of the
causal role of genetic-based predictors in disease (Burgess and
Thompson, 2013).
FEATURE SELECTION
Feature selection refers to the decision about which genetic vari-
ants are most effective in determining the medical trait and
should therefore be included in a predictive model. For example,
it would seem reasonable to include SNPs in the CFH, ARMS2,
C3, and C2/CFB/SKIV2L regions in a model predicting AMD
because the evidence for correlation between AMD and these
variants is both substantial and well-established. Further, selec-
tion of these variants for inclusion in a predictive model would
be prioritized over other variants with little or no evidence of
utility in AMD prediction. Jakobsdottir et al. have investigated
the properties of individual disease-susceptibility SNPs, showing
that SNPs with highly significant odds ratios may be insuffi-
cient to classify individuals (Jakobsdottir et al., 2009). There are
several different methods that can be employed. For a general
review see Guyon and Elisseff (2003). Care must be taken when
internal validation techniques are applied to datasets, as the fea-
ture selection must be incorporated in the internal validation
www.frontiersin.org June 2014 | Volume 5 | Article 162 | 5
Schrodi et al. Genetic-based prediction of disease
routine. Ideally, feature selection should be replicated in an inde-
pendent sample set. Approaches based on stepwise selection of
features are popular. The performance of models constructed
based on a stepwise selection can be evaluated based on model
fit, accounting for the complexity of the model—the Akaike and
Bayesian information criteria are examples of measures to do
this (Akaike, 1974; Schwartz, 1978). Aside from purely statisti-
cal and computational approaches, use of biological information
can improve the selection of genetic markers. By integrating
information from numerous decades of biochemistry, molecular
biology and cellular physiology—the direct phenotypes of genetic
variants—one can construct predictive models weighted toward
those variants segregating in functionally relevant regions in an
effort to improve the robustness of the model and ease of appli-
cation to related phenotypes. For example, if one is generating
a genetic-based predictive model for Crohn’s disease response to
IL-17 monoclonal antibody therapy, higher prioritization of vari-
ants within IL-17-related genes or those polymorphisms that are
known to modify T-helper cells expressing IL-17 (Th17) activity
may provide complementary information and yield a higher like-
lihood of the test having utility when applied to other populations
or related phenotypes.
GENETIC RISK SCORES
Genetic Risk Scores (GRS), determined simply on the basis
of published GWAS results, are among the simplest meth-
ods employed for genetic prediction. The majority of these
approaches construct the predictive model based on the sum
of predisposing genotypes that each individual carries, either
unweighted or weighted by the effect size of the specific predis-
posing genotypes. The essential approach is to take a weighted
sum of risk alleles, choosing the risk alleles based on those found
to be genome-wide significant in a recent meta-analysis (e.g.,
for BMI, see Speliotes et al., 2010). Weights are determined for
each risk allele by the β estimates from the meta-analyzed GWAS.
Unweighted GRS treat each risk locus equally. To illustrate the
weighted GRS approach, assume that k SNPs are known to be
genome-wide significant and further assume that the correspond-
ing β weights from the GWAS are denoted as wi for the ith
SNP. Then the be calculated as: GRS = ∑ki wiRi; where Ri is the
number of risk alleles at the ith SNP. Speliotes et al., using 32
confirmed obesity-associated loci, showed the distribution of the
weighted number of risk alleles across the population used in
the Atherosclerosis Risk in Communities (ARIC) study, and pre-
sented a corresponding AUC for the GRS (Speliotes et al., 2010).
Although significantly different from that expected under the
null, the AUC for this example was exceedingly modest (0.515),
where flipping an unbiased coin would be expected to have an
AUC of 0.500. In another example, Ripatti et al. developed a
genetic risk score based on 13 SNPs discovered to be associated
with coronary heart disease, myocardial infarction or both, in
seven reports (Ripatti et al., 2010). For each individual, the effects
of these SNPs were combined by summing the number of risk
alleles and the resulting risk score was partitioned into quin-
tiles for the purpose of creating a categorical variable. Comparing
extreme quintiles, the authors found roughly a 1.7-fold increased
risk for coronary heart disease in the top risk quintile compared
to the lowest risk. The genetic risk score did not show a significant
effect of the net reclassification of individuals over traditional risk
factors and family history. The combined genetic effect was able
to slightly improve the risk classification of those individuals who
were previously thought to have intermediate risk as determined
by traditional risk factors, but may not have strong clinical util-
ity. Increasing the number of informative genotypes and/or the
traditional risk factors may improve the prognostic performance
of GRS. Other applications, including age-related macular degen-
eration, exhibit more promising performance (Grassmann et al.,
2012; Seddon et al., 2014).
REGRESSION METHODS
Regression methods, familiar tools for constructing prediction
models for both dichotomous and quantitative traits, can lead
to more general predictive models than simple GRSs. One of
the first reports of a cohesive method using multiple replicated
markers under a general logistic regression model was devel-
oped by Yang et al. (2003). Yang and coworkers proposed using
a general logistic regression model to estimate the ratio of the
probability of the genotype information given disease to the
probability of the genotype information within the non-diseased
population. Incorporation of covariates and interaction effects
are possible with this generalized form. Currently, regression
is still commonly used for disease prediction. For example, a
search of PubMed revealed 10 articles published in 2013 which
applied regression methods for the prediction of a variety of
diseases, including cerebrovascular disease, age-related macular
degeneration, and hypertrophic cardiomyopathy (Abraham et al.,
2013; Borque et al., 2013; Gruner et al., 2013; Harada et al.,
2013; Mondul et al., 2013; Romano et al., 2013; Schellekens
et al., 2013; Sharma et al., 2013; Tsai et al., 2013; Uddin et al.,
2013). In addition, extensions including regression of the whole
genome using a Best Linear Unbiased Prediction method (G-
BLUP) can produce more highly predictive models (de Los
Campos et al., 2013). Importantly, Yang et al. (2009) pointed
out that one should not rely on point estimates alone, but also
provide a measure of the uncertainty of the risk estimates. Risk
estimates depend on a variety of parameters, each of which
may be estimated with some uncertainty. Cumulative uncertainty
across all estimated parameters leads to uncertainty of the risk
estimates.
There are several modeling assumptions made when applying
either linear or logistic regression but, in the specific application
area of genetics, the following concerns should be emphasized.
First, multicollinearity between nearby markers is usually a seri-
ous concern. For markers in high linkage disequilibrium with
each other, it is common to select the variant with the lowest p-
value for inclusion in the model. Principal component regression
is another useful way to address concerns arising from mul-
ticollinearity. For example, Gauderman et al. found that this
approach performs well when applied to a single candidate gene
(Gauderman et al., 2007). Another concern is marker-marker
interactions. For parsimony, it is common practice to ignore
interactions. Interaction analysis is not easy to conduct and can
be computationally intensive. Furthermore, substantially larger
sample sizes are typically needed to detect interaction effects than
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are needed to detect main effects. However, ignoring interac-
tions may underestimate genetic effects, and improvements in
the understanding of interactions would be expected to improve
genetic risk prediction models (Thanassoulis and Vasan, 2010).
Missing data are commonly problematic since genotype success
rates are never perfect (Kim and Misra, 2007). One strategy is to
drop samples with missing data (Schwender and Ickstadt, 2008).
Otherwise, when possible, imputation can be a useful solution for
“filling in” missing data (Yuan, 2000).
Usually, for presence vs. absence of disease phenotypes, a
predictive model is first developed by analyzing a case-control
dataset, and then applied to a particular population. To provide
risk estimates that are calibrated to that particular population, an
adjustment which depends on the case to control ratio must be
made to the intercept term of the case-control regression model
(Yang et al., 2003).
Many studies, but not all (Warren et al., 2014), indicate that
risk prediction would be more accurate if more predictors could
be added in the risk model (De Jager et al., 2009; van Dieren
et al., 2012). But the confidence interval (CI) of the risk esti-
mate is often not considered in the evaluation of the risk model.
When the model is built using regression in a meta-analysis of
many case-control datasets, confidence intervals are often not
even estimated.
Provided it is unbiased, a more precise risk estimate with a
smaller CI from a model with fewer predictors is better than a
less precise risk estimate with a larger CI from a model with
more predictors (Shan et al., 2013). To compute the CI for the
risk estimates from a meta-analysis, each individual study in the
meta-analysis should do a joint analysis and return coefficient
estimates and the variance-covariance matrix for the coefficients.
Then, these can be combined to estimate the overall variance-
covariance matrix and a precise CI for the risk estimates. Goddard
et al. developed a method that derives an empirical CI combin-
ing all relevant sources of variation in disease risk (Goddard and
Lewis, 2010; Crouch et al., 2013).
BAYESIAN NETWORKS
Bayesian Networks have resulted from the application of advances
in graph theory to applied probability and carry a high degree of
interpretability, along with providing an intuitive framework for
obtaining posterior probabilities and the treatment of classifica-
tion problems (Pearl, 1988; Jordan, 2004). If the features (genetic
markers) within the BayesianNetwork can be reasonablymodeled
as being conditionally independent (conditional on the disease
trait in our application), then the network is reduced to a highly
tractable Naïve Bayes model. Given a set of n genetic markers,
using Bayes’ rule one can write the posterior probability of the
disease trait (PPD), as:
PPDn = P
(
D
∣∣∣ ⋂n
i= 1 Gi
)
= P
(⋂n
i= 1 Gi
∣∣ D) P(D)
P
(⋂n
i= 1 Gi
) ,
where D denotes a random variable for the disease trait and n
genetic markers are used in the prediction. Under the condi-
tional independence assumption of Naïve Bayes, we can com-
pletely factorize the product and, for a binary trait (D = 1 to
denote disease and D = 0 for non-disease), one can re-write
the PPD as:
PPDn =
P(D = 1)∏ni= 1 P(Gi | D = 1)
P(D = 1)∏ni= 1 P(Gi | D = 1) + P(D = 0)∏ni= 1 P(Gi | D = 0) .
To illustrate this type of calculation, Figure 1 shows scaled PPD
values for a rheumatoid arthritis study. In this study (Chang
et al., 2008), the PPD for every possible three-locus genotype
combination at the risk loci (HLA-DRB1, the R620W polymor-
phism at PTPN22, and diplotypes at TRAF1) was calculated,
and scaled such that the smallest value was set to 1; SRR denotes
this scaled ratio (Figure 1). While there is substantial variability
across the values for different genotype combinations: over a
41-fold difference in predicted rheumatoid arthritis-risk, it is
important to keep in mind how these bins are populated with
individuals with and without the disease trait (the case-control
frequencies given for each combination), for a prognostic loses
general utility as intermediate combinations become frequent.
In concrete terms, while a 41-fold difference is impressive, only
0.1% of the general population is calculated to carry genotypes
producing this level of effect. 3.2% have multi-locus genotypes
that generate at least a 21-fold increase in RA risk, and 13.7%
carry a multi-locus genotype with >5-fold increase in RA risk
(all compared to the lowest category).
Figure 2 displays the results from a simplified model. Five
hundred disease susceptibility SNPs, all having equal effect sizes
and genotype frequencies, were modeled. A prior probability of
disease was set to 0.20 and the predisposing genotype frequency
FIGURE 1 | Rheumatoid arthritis scaled posterior probabilities (SRR).
Genotype data at three strongly predisposing loci, HLA-DRB1, TRAF1, and
PTPN22 are combined and the posterior probabilities calculated for every
possible multilocus genotype combination. The prior probability was set to
the approximate population prevalence of rheumatoid arthritis, 0.01. The
posterior probabilities are scaled such that the lowest RA-risk multilocus
genotype was set to a value of 1. The results show a 41-fold variation in
posterior probabilities. The expected frequencies of the various multilocus
genotype combinations in RA patients/controls are shown at the top of
each bar.
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FIGURE 2 | Posterior probability variation with relative risk. The
density of posterior probabilities of disease (PPD) are shown under a
simplified multilocus disease model. The number of independent,
disease-predisposing SNPs was set at 500. Relative risk was modeled as
being identical for each predisposing SNP. Frequency of the predisposing
genotype in controls was set to 0.05 at each SNP. Prior probability of
disease was set at 0.20. Naïve Bayes was used to calculate posterior
probabilities. The data points only take on discrete values (The densities
are composed of discrete values which are connected by lines to
produce the curves. While the sum of the discrete values all equal one
in each of the curves, the areas under the curves do not), but are
presented with interconnecting lines.
in the general population was set to 0.05 for all 100 SNPs. As
expected, for very small effect sizes the number of individuals
calculated to have posterior probabilities close to 0.20 is high
and rapidly tails off. However, for larger effect sizes, there is an
accumulation of individuals with posterior probabilities closer to
1 and 0. Interestingly, even with quite considerable effect sizes
(for high frequency alleles) much of the density still resides in
the intermediate region between 0.10 and 0.90. If we explore the
dynamics as the number of loci is increased, so does the variance
in the posterior probability of the disease trait (Figure 3).
Diagnosis or prognosis of disease traits with genetic informa-
tion are classical problems of classification and clustering within
machine learning. Hence, numerous machine learning methods,
such as neural networks, support vector machines, and random
forests can be applied to these types of data sets. Currently, the
use of these methods to address problems using gene expression
is arguably more advanced than the analogous methods applied
to DNA variation data.
QUANTIFYING PROGNOSTIC UTILITY
Within a population studied, once each individual is (1) assigned
a score for a risk metric, (2) assigned a posterior probability,
(3) clustered or (4) classified, a method for assessing prognostic
utility is required to quantify the usefulness in clinical practice.
The most common method used is the area under the ROC
curve, or AUC. However, although this metric is useful to assess
discrimination, it is not the appropriate measure to assess a pre-
dicted probability (Cook, 2007). Graphically, the ROC curve is
a plot of the performance of the predictor in a space defined
by the sensitivity (true positive rate) and 1—specificity (false
positive rate). Varying the threshold of calling a result positive
or negative, a curve can be produced for the predictive model.
The AUC is the integral of the curve. For a completely non-
informative predictor, the AUC is 0.50, with larger values (up to
unity) indicating improved prognostic utility (Figure 4). While
useful, sensitivity and specificity are probabilities conditional on
the state of the phenotype trait. One may want to consider met-
rics that have differential performance with the prevalence of
the disease trait. Indeed, all other diagnostic factors being equal,
a physician should be more prone to diagnose an individual
with a more common phenotype than an exceedingly rare one,
because the a priori likelihood of the disease being the common
phenotype is higher than the likelihood for the rare phenotype.
Therefore, use of positive and negative predictive values (PPV and
NPV) may be more useful in the clinical setting. PPV is defined
as the proportion of true positives out of all positive results as
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FIGURE 3 | Posterior probability variation with number of predisposing
loci. The density of posterior probabilities of disease (PPD) is shown under a
simplified multilocus disease model. The relative risk of each independent,
disease-predisposing SNP was set to 2.0. Prior probability of disease was set
at 0.20. Frequency of the predisposing genotype in controls was set to 0.05
at each SNP. The number of predisposing loci was increased from 20 to 1000.
Naïve Bayes was used to calculate posterior probabilities. The data points
only take on discrete values (the larger number of loci have many more data
points reflecting the larger number of possible multilocus genotype
combinations), but are presented with interconnecting lines.
determined from applying a diagnostic test. Conversely, NPV is
defined as the proportion of negative results that are indeed truly
negative. However, a direct ROC analog of characterizing the
tradeoff between PPV and NPV offers challenges. Motivated by
this, Pencina et al. suggest that averaging over PPV and NPV
may provide an improved metric for characterizing prognos-
tic/diagnostic utility (Pencina et al., 2008). In 2006, a newmethod
for characterizing disease predictions based on proportions of
individuals accurately reclassified was presented (Cook et al.,
2006). This approach was further developed in subsequent pub-
lications, describing the employment of the Hosmer-Lemeshow
goodness-of-fit statistic and the net reclassification improvement
statistic applied to reclassification categories as predictive mea-
sures (Cook, 2007; Cook and Ridker, 2009). The authors applied
these approaches to better specify results from cardiovascular risk
models.
Another approach would be to characterize the improvement
in the distribution of posterior probabilities as compared to the
distribution of prior probabilities, where the distribution is taken
across all individuals evaluated. The more informative the genetic
information becomes, the larger the departure between poste-
rior and prior probability densities. A natural measure for this is
the Kullback-Leibler Divergence, which quantifies the departure
between two densities (Kullback and Leibler, 1951). Applied to
characterizing the improvement in disease prediction following
the interrogation of a suite of features such as genetic markers,
the Kullback-Leibler Divergence is defined as:
DKL =
∑
P(Disease |G1, . . . ,Gn) log
[
P(Disease |G1, . . . ,Gn)
P(Disease)
]
where Gi are the random variables describing the states of each
genetic marker involved in disease susceptibility, and the sum is
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FIGURE 4 | AUC. The figure shows the ROC curve and corresponding area
under the ROC curve (AUC). The expected patterns under two extreme
scenarios are shown: an ideal diagnostic scenario and the pattern expected
using random predictions.
over all possible multilocus genotype combinations.DKL is calcu-
lated across the entire population to whom the predictive model
is applied. Larger values of DKL indicate enhanced differences
between the posterior and prior probabilities across the popu-
lation, reflecting the greater utility of the genetic information.
Hence, the Kullback-Leibler Divergence concurrently captures
both the magnitude of the effect the genetic data have on the pos-
terior probabilities for each individual (compared to the prior)
and the proportion of tested individuals exhibiting each magni-
tude of the effect. Empirical-based calibration of this or other
measures of prognostic utility can often be accomplished through
using well-studied data sets having standard prognostic tests such
as the Framingham population and cardiovascular disease risk
score (Wilson et al., 1998; Schrodi et al., 2009).
Another possible method for characterizing would be to define
some level of probability that is clinically meaningful for the spe-
cific application. That is, define critical levels τpos and τneg such
that exceeding these values with the posterior probability of dis-
ease provides actionable information for a clinician. Define the
conditions:
C1: P
(
Disease |Genotype Data, other features) > τpos
C2: P
(
Disease |Genotype Data, other features) < τneg .
We explore the dynamics of C1 and C2 as a function of the
prior probability of disease in Figure 5. The collective effect of
100 disease-predisposing SNPs, each with relative risk 2.0 and
genotype frequency 5%, is clearly not sufficient to concurrently
generate high proportions of individuals who are well-classified
as either being likely (C1) or unlikely (C2) to have disease. At
prior probabilities close to 0.50, the majority of individuals do
not satisfy either condition C1 or C2. It is only in the situations
where the prior probability is either close to 0 or 1 that large per-
centages of the population interrogated achieve very high or very
low posterior probabilities. Hence, with current results from dis-
ease genetics, it seems reasonable to assume that a clinician should
already have a strong suspicion either of a disease diagnosis or the
exclusion of a disease to warrant the use of SNPs.
To further explore these prognostic utility patterns, we con-
sidered two simplified disease models: a highly polygenic model
FIGURE 5 | Effect of prior probability. The frequency of multilocus
genotype combinations exceeding the C1 and C2 thresholds for posterior
probabilities of disease (PPD) (set at 0.05 and 0.95, respectively) are
presented as a function of the prior probability of disease. 100 predisposing
SNPs were used in the model, each having a predisposing genotype
frequency of 5% in controls and relative risk of 2.0.
consisting of 1000 predisposing SNPs, each of appreciable fre-
quency (10% in controls) (Figure 6). We set the prior probability
of disease to 0.20. As the relative risk of each SNP is increased
from 1.02 to 1.80, the C2 condition exhibits a sigmoidal pattern,
climbing to over 80% roughly when the relative risk hits 1.45.
In contrast, the C1 condition peaks at roughly the same relative
risk and declines thereafter, but never exceeding 0.02. A typi-
cal large GWAS experiment would be well-designed to identify
the SNPs with relative risks in excess of roughly 1.1. The collec-
tive effect from the 1000 SNPs is not sufficient to overcome the
prior probability of 0.20 to promote frequent individual mul-
tilocus genotype combinations to exceed the 0.95 threshold of
C1. That said, the proportion of individuals with posterior prob-
abilities exceeding the C2 < 0.05 threshold was much higher.
We explored a highly penetrant, rare allele model (Figure 7). We
constructed this model with 100 predisposing single nucleotide
variants (SNVs) with predisposing genotypes being rare (0.1%),
offset by large effect sizes ranging from relative risks of 10 to
400. Sequencing studies generate numerous SNVs. In each graph
a single effect size was assumed for all SNVs. Again, the prior
probability was set to 0.20. Here, the C1/C2 dynamics are more
complex, with the C1 and C2 conditions being very sensitive to
individual multilocus genotype combinations. Modeling a dis-
tribution of SNV frequencies would smooth this type of graph.
These are overly simplified cases examined here and the param-
eter space is vast—additional work in this area would provide
useful insights into the properties of prognostics that result from
different genetic-based disease models. That said, the proportion
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FIGURE 6 | Highly polygenic model. The dynamics of the C1/C2 threshold
values under a simplified model is shown as the relative risk of the SNPs
varies. The highly polygenic model has 1000 predisposing SNPs each
having predisposing genotype frequencies in controls equal to 10% and a
prior probability equal to 0.20. The relative risk was varied from 1.02 to 1.80.
of individuals satisfying C1 is dramatically higher than under
the highly polygenic model. Further, high values of C1 and C2
occur concurrently. Although much more work is needed to fully
explore these dynamics, this observation may give some hope to
the usefulness of rare, highly penetrant sequence variants in the
context of disease prediction. However, one might have expected
that the most common results of GWAS analyses—identification
of large numbers of common variants each with small impact
on disease risk for common diseases—would be more useful,
unless there are other effects operating, such as considerable locus
heterogeneity for common diseases.
EXAMPLES
GWAS DATA APPLIED TO A TYPE 2 DIABETES PROSPECTIVE COHORT
Type 2 diabetes (T2D) is a common medical condition with
rapidly increasing incidence worldwide (Zimmet et al., 2001).
This disease is characterized by a multitude of abnormal patho-
physiological states involving muted beta cell response, chronic
inflammation, and aberrant levels of metabolic markers that
ultimately lead to vascular damage, infection, heightened car-
diovascular disease risk, and neuropathy (Zimmet et al., 2001).
Numerous T2D GWAS have been conducted and have reliably
identified new genes and genetic regions involved in T2D sus-
ceptibility, albeit with modest effect sizes (McCarthy, 2010).
Early prediction of T2D onset and trajectory can be leveraged
into improving important medical decisions, including treatment
with therapeutics, exercise programs, and diet restriction. It is
possible that genetic variants may play a role in improving the
prediction of T2D. To test this idea, Shigemizu et al. very recently
FIGURE 7 | Highly penetrant model. The highly penetrant model uses
100 SNPs each having a predisposing genotype frequency of 0.1% and also
a prior probability of 0.20. The relative risk takes on values from 10 to 400.
Although the highly polygenic model yields a large proportion of individuals
with posterior probabilities below 0.05, the increasing relative risks have
little impact on the proportion of individuals with posterior probabilities
above 0.95. The highly penetrant model shows an overall increase in the
proportions of individuals with posterior probabilities below 0.05 and above
0.95, but the patterns are somewhat unexpected (not smooth, nor
monotone). These patterns are generated from all predisposing SNVs
having identical genotype frequencies and relative risks, coupled with
having specific PPD thresholds.
performed a two-stage study (training and test sets) that resulted
in combining nine SNPs with three clinical risk factors (age, gen-
der, and BMI) to develop a predictive model for T2D in a prospec-
tive cohort having Japanese ancestry (Shigemizu et al., 2014).
The features used in a regression model for T2D-prediction were
selected using a Bayes Factor and lassomethod. From both genetic
and clinical risk factors, the resulting predictive model showed
reasonable AUC values in the independent test set (AUC= 0.808).
Further, where the sensitivity and sensitivity were concurrently
maximized, the model yielded a PPV and NPV of 77.8 and 73.8%,
respectively. Although the selected SNPs did add to the diagnos-
tic performance of the prediction model, they only did so in an
incremental fashion. The model using SNPs, interactions, and
clinical risk factors exhibited a 1.5% increase in the AUC over
the clinical risk factors alone. Perhaps the discovery of additional
T2D risk variants from sequencing efforts, rarer exome variants,
extensive epistatic models, and/or undiscovered epigenetic factors
will drive further work in this area to markedly improve the per-
formance of T2D predictive models using heritable information.
Until then, there may be greater gains through the use of dynamic
markers like metabolite profiling and proteomics. Alternatively,
exploration of prediction within T2D subgroupsmay offer amore
fruitful avenue of inquiry.
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STROKE PREDICTION USING GENETIC RISK SCORES
Stroke events are major contributors to mortality and morbid-
ity, constituting the fourth leading cause of death in the United
States. Accurate prediction of ischemic stroke risk would enable
medical interventions to at least partially remediate stroke occur-
rence and the resulting brain damage. Very recently, two large
studies (Ibrahim-Verbaas et al., 2014;Malik et al., 2014) have been
published evaluating risk models constructed from a number of
stroke and related phenotype-associated GWAS SNPs. The results
were consistent with GRSs achieving statistical significance, but
adding little in diagnostic utility to clinical features, as measured
by AUC. Ibrahim-Verbaas et al. evaluated the performance of
a 324-SNP GRS in four population-based cohorts totaling over
22,000 individuals in an effort to improve the discrimination of
ischemic stroke over that generated from the Framingham Stroke
Risk Score Model, age and sex. The SNPs were selected based
on association with stroke-related phenotypes and a GRS con-
structed using weights from the regression model used to test
the disease association. ROC curves from the results for the study
show that the weighted GRSs do not substantially add to the AUC
over that achieved by the Framingham Stroke Risk Score and
sex—the improvement in AUC from the GRS was approximately
0.02 for all stroke as well as for ischemic stroke alone—although
the AUC improvement was statistically significant. The authors
also examined the impact of the GRS on the net reclassification
index, showing statistically significant, but incremental improve-
ment. Concurrently published in the same issue of Stroke, Malik
et al. presented similar results for their stroke GRS performance in
comparison to clinical features using overlapping samples (Malik
et al., 2014). The study showed increased stroke risk across quin-
tiles of their GRS, obtained from an analysis of independent
samples from theWellcome Trust Case Control Consortium 2 and
theMETASTROKE consortium. Slightly under a 1.5-fold increase
in risk was found comparing the top quintile to the middle quin-
tile, and a >2-fold increase comparing the lowest quintile to the
top quintile. No significant improvement in the net reclassifica-
tion was observed and the ROC curves with and without the
GRS are virtually superimposable for a sample set composed of
a clinical trial-based derivation sample set and the replication
sample set.
PREDICTION USING BIOBANK DATA
Current efforts to discover and employ genetic risk predictors
across multiple health care systems include those of the Electronic
Medical Records and Genomics (eMERGE) Network (Gottesman
et al., 2013). The eMERGE Network has supported large-scale
genotyping efforts in biobanked DNA samples linked to elec-
tronic medical records. As such, a repository of genome-wide
genetic data can be interrogated with respect to a vast amount
of clinical information. One use of these data is to investigate how
sets of genetic markers can stratify sample sets for the purpose
of performing historical prospective studies. By analyzing longi-
tudinal data, one can specify the sets of individuals to “follow”
from a point in time to test for association with various medical
traits. In doing so, one can perform a prospective study relat-
ing genotypes to the accumulation of various medical outcomes
and laboratory values. This is an excellent venue for evaluating
genetic-based predictive models. For example, suppose one con-
structed a predictive model for myocardial infarction (MI) with
existing literature findings and then assigned a predicted MI risk
for each individual. One could then evaluate how the predicted
risk was correlated with the actual conversion rate of non-MI
individuals to MI disease states. One can also simultaneously per-
form association testing between any combination of sequence
variants and/or GWAS SNPs and prospectively occurring disease,
for the purpose of discovering novel genotype-phenotype corre-
lations. Notably, this type of experimental design is less subject to
confounding effects when compared to retrospective case-control
designs because a cohort-based design is less likely to impart bias
from sample selection being correlated with genetic factors. As
noted in a 2010 Institute of Medicine “Rapid Learning” docu-
ment, the hope is that electronic medical records, biobanks and
bioregistries will provide evidentiary support for intervention
decisions (National Research Council, 2010). Interesting, Lauer
and D’Agostino recently suggested that the next disruptive tech-
nology in clinical research would be the randomized registry trial
(Lauer and D’Agostino, 2013).
Deeply phenotyped biobanked datasets can also be used to
redefine disease states. GWAS have highlighted SNPs that are
undoubtedly correlated with susceptibility to common diseases
but, as we have discussed, the alleles discovered thus far explain
only a marginal amount of disease heritability. The reasons for
this are the subject of much debate. Resolution of this perplex-
ing problem will likely involve a multitude of discoveries, not the
least of which stem from addressing the opaque correspondence
between clinical phenotypes and underlying molecular patholo-
gies. Due to reliance on observations of complex, gross physiology
in the clinic, it is reasonable to assume that there may be multi-
ple molecular etiologies that map to a single clinical disease state
(e.g., estrogen receptor status now meaningfully partitions pre-
viously indistinguishable breast cancers and leads to profound
changes in the use of Tamoxifen) (Fisher et al., 1988, 1989; Paik
et al., 2004). Conversely, single molecular perturbations may have
pleiotropic effects (e.g., the rs2476601 SNP in PTPN22 is strongly
associated with several, clinically distinct autoimmune diseases)
(Begovich et al., 2004; Bottini et al., 2004; Kyogoku et al., 2004;
Velaga et al., 2004; Canton et al., 2005; Criswell et al., 2005). The
medical field is accustomed to defining diseases with regard to
visual inspection and gross anatomical measurements, and there-
fore may (1) aggregate disparate molecular pathophysiologies and
(2) partition the same molecular processes into different disease
classes. Indeed, there is not a one-to-one mapping between clini-
cal assessments of disease and molecular processes. Thus, it seems
reasonable to adopt the reductionist stance that redefining dis-
ease states and processes in terms of the underlying genetic and
molecular variation may significantly aid investigation of dis-
ease etiologies. In this way, one can construct phenotype-based
predictive models for sets of genetic/molecular information—a
reverse genetics approach. Several groups have recently taken this
approach to mapping disease genes: Pendergrass et al. used this
method to interrogate data from the PAGE network (Pendergrass
et al., 2013), Hebbring et al. (2013), have performed similar
types of studies in the Marshfield PersonalizedMedicine Research
Project samples, and Denny et al. utilized data from the eMERGE
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Network (Denny et al., 2013). In these studies, clinical pheno-
types are screened in electronic medical record (EMR) systems for
association with specific genetic variants with known function (or
highly likely to have specific impact on biological pathways)—a
method pioneered by Ritchie et al. in a large-scale effort to repli-
cate numerous associations using DNA databanks linked to EMRs
(Ritchie et al., 2010). Novel disease associations can be discovered
through these “PheWAS” studies. In addition, this “bottom-up”
(specific genetic variants-to-phenotype) approach can also be
viewed as a starting point for using genetic information to rede-
fine disease states in a classification system that more closely
mirrors the underlying molecular pathophysiology. For example,
screening diseases within a biobank for association with IL23R
missense variants uncovers sets of disease phenotypes where aber-
rant Th17 signaling plays a pathogenic role. Autoinflammatory
diseases, including ankylosing spondylitis, psoriasis, and Crohn’s
disease, would all show a common, core aspect to their molecular
pathophysiology. Additionally, partitioning by these same vari-
ants allows elucidation of disease subgroups. This reclassification
can further enable disease prediction, for the phenotypes pre-
dicted would exhibit clearer correspondence with the underlying
molecular mechanisms.
INFLAMMATORY ARTHRITIS PREDICTION IN THE MARSHFIELD
POPULATION
To illustrate how to apply machine learning methods to empiri-
cal datasets for the purpose of disease prediction and show some
of the difficulties with attaining strong predictive signals from
GWAS findings, we present an example of using genetic data and
samples from an EMR-linked biorepository for the purpose of
distinguishing between inflammatory arthritis conditions.
Worldwide and within the US, inflammatory arthritides are
common conditions representing a substantial portion of dis-
abling disease. Early treatment of these conditions can provide
substantial benefit in averting disabling articular damage and
systemic complications. In general, autoimmune and autoinflam-
matory diseases such as rheumatoid arthritis and spondyloarthri-
tides have significant heritabilities—a substantial portion of
which has been explained by identified polymorphisms, thereby
motivating the incorporation of genotype information into prog-
nostic approaches. This study aimed to investigate and charac-
terize the ability of a panel of genetic markers, identified from
genome-wide association study results, to classify individuals into
the three inflammatory arthritis categories: rheumatoid arthri-
tis, axial spondyloarthritis and psoriatic arthritis (Table 1). Using
genotyped samples from an independent sample set from Central
Wisconsin (Marshfield Clinic), several machine learning meth-
ods were applied to a filtered set of these polymorphisms to
classify individuals into the three inflammatory arthritis dis-
eases, blinded to the known disease status. The WEKA software
package was used to implement the machine learning algo-
rithms (Holmes et al., 1994; Hall et al., 2009). Accuracy was
defined as the proportion of positive and negative classifica-
tion results that were in fact true. The Naïve Bayes classifier
attained the highest average accuracy from 10-fold cross val-
idation on the training set (Table 2). However, when applied
to the Marshfield test set, there was a substantial decline in
Table 1 | Illustration of machine learning methods applied to genetic
data: feature selection.
Ankylosing spondylitis Psoriatic arthritis Rheumatoid arthritis
Rs13203464 (HLA-B27) Rs10484554 (HLA-C) Rs660895 (HLA-DRB1)
Rs30187 (ERAP1) Rs20541 (IL13) Rs2476601 (PTPN22)
Rs11209026 (IL23R) Rs13017599 (REL) Rs3761847 (TRAF1/C5)
Rs10865531 (2p15) Rs2066808 (IL23A) Rs3890745 (MMEL1)
Rs2310173 (IL1R2) Rs12924903 (RUNX3) Rs13031237 (REL)
Rs4333130 (ANTXR2) Rs4795067 (NOS2) Rs7574865 (STAT4)
Rs378108 (21q22) Rs4379175 (IL12B) Rs548234 (PRDM1)
Rs2297909 (KIF2B) Rs4982254 (PSMA6) Rs2327832 (TNFAIP3)
Rs10045431 (IL12B) Rs13151961 (IL2/21) Rs1569723 (CD40)
Rs10903118 (RUNX3) Rs11209026 (IL23R) Rs11574914 (CCL21)
Rs7720838 (PTGER4) Rs7720838 (PTGER4) Rs11172254 (KIF5A)
Rs2058276 (Y-marker) Rs231804 (CTLA4)
Rs1160542 (AFF3)
Rs13151961 (IL2/21)
SNPs were selected for the Naïve Bayes Algorithm to determine inflammatory
arthritis categories. Feature selection for the SNPs was performed through a lit-
erature search on the three diseases of interest from existing GWAS studies:
Ankylosing spondylitis (AS), Psoriatic arthritis (PsA), and Rheumatoid arthritis
(RA). The most significant and replicable SNPs were used to construct the
entire set. Subsequent evaluation of features used Wrapper Subset Evaluation,
ChiSq Attribute Evaluation, Classifier Subset Evaluation, and Information Gain
from Attributes methods within the program WEKA. These methods were cou-
pled with a variety of search methods including genetic algorithm-based, Greedy
Stepwise Selection, and Linear Forward Search methods within WEKA.
Table 2 | Relative performance across machine learning methods.
Algorithm Number Accuracy (%) 10-fold CV
of SNPs accuracy (%)
Decision tree 33 87 74.1
Neural network 5 76 77.1
Logistic regression 24 78 77.7
Support vector machine 1 73 72.6
K-nearest neighbor 7 77 77.2
Naïve bayes 29 78 77.9
Six Machine Learning algorithms using feature selection and classification were
evaluated for accuracy using complied data from the literature in a synthetic
training data set. Effect sizes and genotype frequencies were estimated from
the literature and incorporated into the synthetic data set to train the algorithms.
Accuracy was defined as the proportion of individuals that were correctly pre-
dicted (either true positives or true negatives). 10-fold Cross Validation (CV) was
performed within WEKA and used as the criterion for selection of an algorithm
to use in the test set from Marshfield. Naïve Bayes exhibited slightly higher CV
accuracy when compared to other algorithms, with a low amount of overfitting.
the performance with an average area under the ROC curve of
0.635 (Figure 8). Although the difference between this observed
AUC of 0.635 and that expected under the null (AUC = 0.500)
is statistically significant, we conclude that additional, orthog-
onal predictive variables, such as clinical features, circulating
cytokine profiles or additional genetic variants, are necessary
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FIGURE 8 | AUC for inflammatory arthritis prediction study for the
Marshfield population. The Naïve Bayes classifier developed using data
from the literature was applied to the Marshfield population of
inflammatory arthritis individuals: Rheumatoid arthritis (RA), Psoriatic
arthritis (PsA), and Ankylosing spondylitis (AS). The model generated an
AUC of 0.635, which was statistically significant via permutation. In
addition, performance on randomized sample sets is shown in red, showing
an expected null performance.
to build a clinically useful prognostic test for classifying these
diseases.
SUMMARY
We have summarized some of the seminal issues in utiliz-
ing genetic information in predictive models for disease traits.
Currently, the application of genetic-based predictive models to
common diseases is, generally speaking, disappointing from both
theoretical and empirical lines of evidence. There are some bright
spots, including AMD, Crohn’s disease, and special applications
to selected populations with increased posterior probabilities
due to non-genetic factors. Additionally, if the current wave of
sequence-based disease gene mapping uncovers sufficient num-
bers of highly penetrant alleles, then these may provide clinically
relevant prognostic utility. Outside of common disease prognos-
tics, tumor genetics, screening for inherited Mendelian disorders,
and some pharmacogenetic applications have exhibited the most
progress over the past five years. The reasons for this stem from
the reduced complexity of the genetic architecture of these traits,
yielding extremely high or extremely low posterior probabilities.
Certainly, many questions in the field remain. As our understand-
ing of the nature of elements that resolve the missing heritability
problemmatures, the path to applying predictive modelingmeth-
ods will become clearer. What needs to fall in place for clinically
useful prediction of complex diseases? We speculate that six
critical steps will aid this process:
(1) Through next-generation sequencing platforms applied to
both linkage and association designs, identification of
additional susceptibility variants will fully cover the allele
frequency spectrum and capture disease-predictive alleles.
However, the discovery of rare, highly penetrant risk alle-
les will be most useful as clinical sequencing becomes
widespread and applied earlier in life.
(2) As other elements besides DNA sequences are inherited and
contribute to phenotypic variance, the interrogation of addi-
tional possible contributors to heritability, including DNA
methylation patterns, histone modifications, transgenera-
tional effects, and other factors correlated with disease traits,
will capture more of the molecularly-defined heritability.
(3) Redefining disease phenotypes to more accurately mirror
the underlying molecular pathophysiology will be critical
in reducing disease complexity and better enable genetic
susceptibility mapping. For example, partitioning diseases
by molecular subtypes will identify physiological subgroups
with clearer correspondence with the underlying genetics.
Within the context of research using biobanks linked to med-
ical records, relevant laboratory tests or imaging information,
or both, would also be valuable.
(4) Considerable progress has been made in the field of machine
learning, where robustmethods have been developed to select
features and use them in predictive models. Applying these
approaches to genetic data in combination with existing labo-
ratory tests, imaging data, and other established medical tests
will offer the best chance of creating viable prognostics.
(5) Metrics that capture prognostic utility in a way that accu-
rately reflects what a clinician requires to inform medical
decisions will be developed.
(6) The application of disease predictive models to diverse clin-
ical populations will clarify the performance and limitations
of proposed predictive models and improve medical practice.
In summary, while prediction will continue to be challenging,
future investigations promise to provide a wealth of informa-
tion, some of which will be clinically useful if considered in the
appropriate context.
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